Skip to main content
Addgene
Open Menu

Enter a sequence to perform a BLAST-based search of Addgene plasmid sequence databases.

Information

In Category

Filter By

We narrowed to 11,615 results for: Vars;

Showing: 11321 - 11340 of 11615 results

  1. Fragmid

    Plasmid Kit
    #1000000237
    Purpose
    Fragmid is a modular toolkit that leverages Golden Gate cloning to enable the rapid creation of CRISPR vectors compatible with various delivery approaches, enzymes, and mechanisms.
    Depositor
    John Doench
    Available Since
    Aug. 1, 2024
    Availability
    Academic Institutions and Nonprofits only

  2. Shen Lab DdCBE assembly kit

    Plasmid Kit
    #1000000212
    Purpose
    The DddA-derived cytosine base editor (DdCBE) assembly kit is a collection of 192 modules harboring repeat variable di-residue (RVD) arrays for any desired target.
    Depositor
    Bin Shen
    Available Since
    March 14, 2023
    Availability
    Academic Institutions and Nonprofits only

  3. FNL Combinatorial Cloning Platform

    Plasmid Kit
    #1000000211
    Purpose
    A collection of Multisite Gateway Entry clone plasmids which can be used in a combinatorial fashion to generate large numbers of tagged expression clones for protein expression in a variety of systems
    Depositor
    Dominic Esposito
    Available Since
    Dec. 22, 2022
    Availability
    Academic Institutions and Nonprofits only

  4. S. cerevisiae Advanced Gateway Destination Vectors

    Plasmid Kit
    #1000000011
    Purpose
    Yeast (S. cerevisiae) Gateway Destination Vectors for tagging and gene expression. Has variety of promoters, origin of replications, auxotrophic markers, and N- or C-terminal fusion proteins
    Depositor
    Susan Lindquist
    Available Since
    July 16, 2011
    Availability
    Academic Institutions and Nonprofits only

  5. pAAV_BiLAMP5e3_jGCaMP8m (AAV1)

    Viral Prep
    #213918-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_jGCaMP8m (#213918). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_jGCaMP8m plasmid DNA. Expression of jGCaMP8m under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  6. pAAV_BiCHATe27_GCaMP6f (AAV1)

    Viral Prep
    #213833-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiCHATe27_GCaMP6f (#213833). In addition to the viral particles, you will also receive purified pAAV_BiCHATe27_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the cholinergic neuron-targeting enhancer E27. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  7. pAAV_BiPVe3_GCaMP6f (AAV1)

    Viral Prep
    #213943-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  8. pAAV_BiPVe4_GCaMP6f (AAV1)

    Viral Prep
    #213939-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiPVe4_GCaMP6f (#213939). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  9. pAAV_BiLAMP5e3_GCaMP6f (AAV1)

    Viral Prep
    #213917-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_GCaMP6f (#213917). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  10. pAAV_BiVIPe4_GCaMP6f (AAV1)

    Viral Prep
    #213859-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_GCaMP6f (#213859). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  11. pAAV_BiSSTe4_GCaMP6f (AAV1)

    Viral Prep
    #213947-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_GCaMP6f (#213947). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  12. pAAV_BiSSTe4_dTomato_nlsdTomato (AAV1)

    Viral Prep
    #213944-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_dTomato_nlsdTomato (#213944). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Tags
    dTomato
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  13. pAAV_BiSSTe10_dTomato_nlsdTomato (AAV1)

    Viral Prep
    #213814-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiSSTe10_dTomato_nlsdTomato (#213814). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E10. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Tags
    dTomato
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  14. pAAV_BiPVe4_GCaMP6f (AAV PHP.eB)

    Viral Prep
    #213939-PHPeB
    Purpose
    Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_GCaMP6f (#213939). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  15. pAAV_BiSSTe4_ChR2_mCherry (AAV1)

    Viral Prep
    #213945-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiSSTe4_ChR2_mCherry (#213945). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the SST interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Tags
    mCherry
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  16. pAAV_BiVIPe4_ChR2_mCherry (AAV1)

    Viral Prep
    #213856-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_ChR2_mCherry (#213856). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_ChR2_mCherry plasmid DNA. Expression of mCherry-tagged channelrhodopsin-2 under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Tags
    mCherry
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  17. pAAV_BiVIPe4_dTomato_nlsdTomato (AAV1)

    Viral Prep
    #213855-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiVIPe4_dTomato_nlsdTomato (#213855). In addition to the viral particles, you will also receive purified pAAV_BiVIPe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the VIP interneuron-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Tags
    dTomato
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  18. pAAV_BiPVe3_GCaMP6f (AAV PHP.eB)

    Viral Prep
    #213943-PHPeB
    Purpose
    Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe3_GCaMP6f (#213943). In addition to the viral particles, you will also receive purified pAAV_BiPVe3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the PV+ basket cell-targeting enhancer E3. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  19. pAAV_BiSSTe10_GCaMP6f (AAV1)

    Viral Prep
    #213818-AAV1
    Purpose
    Ready-to-use AAV1 particles produced from pAAV_BiSSTe10_GCaMP6f (#213818). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E10. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only

  20. pAAV_BiSSTe4_GCaMP6f (AAV PHP.eB)

    Viral Prep
    #213947-PHPeB
    Purpose
    Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe4_GCaMP6f (#213947). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the SST interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.
    Depositor
    Gordon Fishell
    Article
    Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1
    Available Since
    Sept. 23, 2025
    Availability
    Academic Institutions and Nonprofits only
Showing: 11321 - 11340 of 11615 results